A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
- PMID: 30203832
- DOI: 10.1111/bjh.15593
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
Keywords: FLT3; acute leukaemia; midostaurin; paediatric; relapsed/refractory.
Similar articles
-
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.Pharmacotherapy. 2017 Dec;37(12):1586-1599. doi: 10.1002/phar.2039. Epub 2017 Nov 23. Pharmacotherapy. 2017. PMID: 28976600 Review.
-
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20. Lancet Oncol. 2017. PMID: 28645776 Free PMC article. Clinical Trial.
-
Midostaurin: First Global Approval.Drugs. 2017 Jul;77(11):1251-1259. doi: 10.1007/s40265-017-0779-0. Drugs. 2017. PMID: 28612232 Review.
-
Midostaurin in FLT3-mutated acute myeloid leukaemia.Lancet Oncol. 2017 Aug;18(8):e439. doi: 10.1016/S1470-2045(17)30506-5. Epub 2017 Jun 29. Lancet Oncol. 2017. PMID: 28669736 No abstract available.
-
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2. doi: 10.1016/j.clml.2015.02.017. Epub 2015 Feb 16. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25776192 Free PMC article. Clinical Trial.
Cited by
-
Molecular Approaches to Treating Pediatric Leukemias.Front Pediatr. 2019 Sep 6;7:368. doi: 10.3389/fped.2019.00368. eCollection 2019. Front Pediatr. 2019. PMID: 31555628 Free PMC article. Review.
-
Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia.Case Rep Oncol. 2020 Mar 24;13(1):266-270. doi: 10.1159/000506194. eCollection 2020 Jan-Apr. Case Rep Oncol. 2020. PMID: 32308588 Free PMC article.
-
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia.Blood Adv. 2021 Dec 14;5(23):5215-5219. doi: 10.1182/bloodadvances.2021005164. Blood Adv. 2021. PMID: 34592761 Free PMC article. No abstract available.
-
Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia.Molecules. 2022 Jun 18;27(12):3911. doi: 10.3390/molecules27123911. Molecules. 2022. PMID: 35745032 Free PMC article. Review.
-
Targeted Therapies in Pediatric Acute Myeloid Leukemia - Evolving Therapeutic Landscape.Indian J Pediatr. 2024 Feb;91(2):176-183. doi: 10.1007/s12098-023-04741-3. Epub 2023 Jul 14. Indian J Pediatr. 2024. PMID: 37450248 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous